Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ecopipam Thorough QT/QTc Study
NCT05841160Phase 1Completed
- Sponsor
- Emalex Biosciences
- Start
- Mar 2023
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ecopipam in Tourette syndrome (TS) and childhood-onset fluency disorder (COFD) (4 arms), sponsored by Emalex Biosciences. Primary endpoint: Ecopipam effect on QTc interval compared to placebo at Day 25. Started Mar 2023; status: completed.
02
Drugs
ecopipam
03
Conditions
Tourette syndrome (TS)childhood-onset fluency disorder (COFD)
Beyond the preview
Go deeper on NCT05841160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05841160.